Telix Pharmaceuticals Announced UK MHRA Approval For Prostate Cancer Imaging Agent Illuccix
TLXFebruary 12, 2025
Read more →Reported Earlier, Telix To Acquire Imaginab's Drug Candidates And Cutting-Edge Antibody Engineering Platform For $45M
TLXJanuary 13, 2025
Read more →Telix Pharma Reported Q4 Revenue Of $142M, Up 46% YoY, FY24 Revenue Of $517M, Up By 55% YoY
TLXJanuary 13, 2025
Read more →Reported Earlier, Telix Expands Theranostic Pipeline With FAP-Targeting Radiopharmaceuticals For Pan-Cancer Treatment
TLXNovember 19, 2024
Read more →UBS Initiates Coverage On Telix Pharmaceuticals with Buy Rating, Announces Price Target of $21
TLXNovember 15, 2024
Read more →